PMC

24-month disease-free survival for all vaccinated patients compared with unvaccinated control patients.

E75 vaccine trial schema. IND = Investigational New Drug.

24-month disease-free survival (DFS) determined for clinicopathologic subgroups. DFS was compared between vaccinated patients and unvaccinated controls in patients with (A) node-positive breast cancer, (B) HER2 low-expressing (IHC 1+ or 2+ or FISH < 2.0) breast cancer, and (C) low-grade (grade 1 or 2) breast cancer.

24-month disease-free survival (DFS) comparing vaccinated patients who received booster inoculation with unvaccinated controls. (A) DFS comparing all vaccinated patients who received at least one booster inoculation prior to 24 months with unvaccinated controls. (B) DFs comparing vaccinated patients who received a booster 6 months after completing the primary vaccine series with unvaccinated controls, with patients having early recurrences (<12 months) excluted.

24-month disease-free survival (DFS) based on dosing regimen. (A) patients who received the optimal dose were compared with unvaccinated controls. (B) patients who required dose reductions due to significant local reactions or ≥ grade 2 systemic toxicity were compared with unvaccinated contols. To date, no patient requiring a dose reduction has had disease recurrence.